Odyssey Health (ODYY) Receivables (2016 - 2024)
Odyssey Health (ODYY) reported Receivables of $45250.0 for Q3 2024, up 4201.33% sequentially from $1052.0 in Q4 2017.
Odyssey Health (ODYY) Receivables (2016 - 2024) Analysis & Trends
Odyssey Health has disclosed Receivables across 3 years of filings, most recently posting $45250.0 for Q3 2024.
- Quarterly Receivables changed N/A year-over-year to $45250.0 in Q3 2024, while the trailing twelve-month figure through Jul 2024 was $45250.0 (changed N/A YoY) and the FY2024 annual result came in at $45250.0, changed N/A from the prior year.
- Receivables climbed to $45250.0 in Q3 2024, from $1052.0 in the prior quarter.
- Across five years, Receivables topped out at $45250.0 in Q3 2024 and bottomed at $45250.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 8.21 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 3.57 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 6.36 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 3.15 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 973.00 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 3.82 Bn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 1.11 Bn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 4.50 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 1.09 Bn |
| 10 | Odyssey Health | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2024 | 45,250.00 |
| Oct 31, 2017 | 1,052.00 |
| Jul 31, 2017 | 1,052.00 |
| Apr 30, 2017 | 1,052.00 |
| Jan 31, 2017 | 1,052.00 |
| Oct 31, 2016 | 11,052.00 |
| Jul 31, 2016 | 18,052.00 |
| Apr 30, 2016 | 22,500.00 |